The Pharmaceutical Benefits Advisory Committee has recommended a change to the listing of a popular class of diabetes medicines and a 15 per cent price reduction.
PBAC says a price reduction of 'at least 15%' would be appropriate
December 19, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
Todd Stephenson confirmed on ACT list for New Zealand election
September 14, 2026 - - Latest News -
Scandal-hit KPMG still holds $37 million in health department work
September 14, 2026 - - Latest News -
Canberra details tax changes with limited concessions for some innovators
September 14, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 11 September
September 11, 2026 - - Podcast -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
AI Health Summit 2026
September 10, 2026 - - Summit
